Collegium Pharmaceutical (NASDAQ:COLL) Stock Price Down 5% – Time to Sell?

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) shares were down 5% during trading on Tuesday . The company traded as low as $46.93 and last traded at $47.0230. Approximately 234,086 shares were traded during trading, a decline of 42% from the average daily volume of 401,852 shares. The stock had previously closed at $49.48.

Analyst Ratings Changes

Several equities research analysts recently issued reports on COLL shares. Wall Street Zen upgraded Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Collegium Pharmaceutical in a research note on Monday, December 22nd. Needham & Company LLC reissued a “buy” rating and set a $46.00 price target on shares of Collegium Pharmaceutical in a research report on Tuesday, October 28th. Barclays assumed coverage on shares of Collegium Pharmaceutical in a report on Monday, December 8th. They set an “overweight” rating and a $58.00 price target on the stock. Finally, HC Wainwright boosted their target price on Collegium Pharmaceutical from $44.00 to $46.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $47.00.

Collegium Pharmaceutical Stock Down 5.2%

The stock’s 50-day moving average price is $44.22 and its two-hundred day moving average price is $37.54. The company has a current ratio of 1.36, a quick ratio of 1.27 and a debt-to-equity ratio of 2.71. The stock has a market capitalization of $1.48 billion, a P/E ratio of 29.18 and a beta of 0.61.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings data on Wednesday, September 4th. The specialty pharmaceutical company reported $1.26 EPS for the quarter. Collegium Pharmaceutical had a return on equity of 102.03% and a net margin of 7.72%.The business had revenue of $135.55 million for the quarter. As a group, research analysts expect that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Insider Activity at Collegium Pharmaceutical

In related news, EVP Scott Dreyer sold 17,600 shares of the business’s stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $48.17, for a total value of $847,792.00. Following the sale, the executive vice president directly owned 103,613 shares in the company, valued at approximately $4,991,038.21. The trade was a 14.52% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Colleen Tupper sold 30,000 shares of the stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $40.53, for a total transaction of $1,215,900.00. Following the transaction, the chief financial officer owned 126,667 shares of the company’s stock, valued at $5,133,813.51. This represents a 19.15% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 51,250 shares of company stock worth $2,235,352. Company insiders own 2.51% of the company’s stock.

Hedge Funds Weigh In On Collegium Pharmaceutical

Several hedge funds have recently made changes to their positions in the stock. Amundi grew its holdings in shares of Collegium Pharmaceutical by 302.1% during the first quarter. Amundi now owns 62,592 shares of the specialty pharmaceutical company’s stock worth $1,816,000 after purchasing an additional 47,024 shares in the last quarter. Bank of New York Mellon Corp lifted its position in Collegium Pharmaceutical by 3.1% during the second quarter. Bank of New York Mellon Corp now owns 249,875 shares of the specialty pharmaceutical company’s stock valued at $7,389,000 after purchasing an additional 7,614 shares during the last quarter. Assenagon Asset Management S.A. grew its stake in Collegium Pharmaceutical by 90.5% in the 3rd quarter. Assenagon Asset Management S.A. now owns 195,589 shares of the specialty pharmaceutical company’s stock worth $6,844,000 after buying an additional 92,898 shares in the last quarter. Fortis Capital Advisors LLC bought a new position in shares of Collegium Pharmaceutical in the 1st quarter worth $408,000. Finally, Rhumbline Advisers raised its position in shares of Collegium Pharmaceutical by 3.1% during the 1st quarter. Rhumbline Advisers now owns 111,628 shares of the specialty pharmaceutical company’s stock valued at $3,332,000 after buying an additional 3,400 shares in the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.